60 Degrees Pharmaceuticals Inc (SXTP) Stock Price, Quote & News

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumoni...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 327 5422

Website: www.60degreespharma.com

Address:

1025 Connecticut Avenue NW, Suite 1000, Washington, United States

ChartChartist Jul. 30 at 7:42 PM

$SXTP nice offerings $PMAX bank central

0 · Reply

Hooparena Jul. 30 at 6:58 PM

$SXTP Just the luck of having multiple press releases of positive advancements of the new drug and the amazing purchase of a 20% stake by Knight and then this news hits. The offering is already spoken for (by Knight, I wonder?) so the stock is not going to be hitting the market anytime soon. Maybe that is why Knight issued the press release yesterday possibly knowing they might have spoken for the new shares and will have to make an additional filing soon. If it was Knight, they double their percentage of shares. Just my thoughts.

0 · Reply

flychicken1991 Jul. 30 at 6:42 PM

$SXTP Negative (91%): SXTP's stock price faces immediate pressure because the placement increases the number of common shares or equivalents and introduces warrants capable of creating up to 574,713 additional shares... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/db3fec30f6260068?utm_source=stocktwits&utm_medium=story_url

0 · Reply

Hooparena Jul. 30 at 2:15 PM

$SXTP Knight Therapeutics taking a 20% stake in the company has the signs of something bigger on the horizon in my opinion. Could the new potential drug be a game changer or could we be on the cusp of a takeover attempt of the company. Knight Therapeutics has a history of investing in big new potential drugs or a takeover of another company.

0 · Reply

redog677 Jul. 29 at 11:48 PM

$SXTP they did leave a voicemail. It was about the shareholders meeting on Wednesday the 5th of Aug. I’ve never received a phone call like that. I thought it was interesting

0 · Reply

redog677 Jul. 29 at 11:45 PM

$SXTP I had a phone call from them today but wasn’t able to take the call.

0 · Reply

llchen1204 Jul. 29 at 11:45 PM

$SXTP tomorrow morning it will run as one of the top gainers

0 · Reply

Stonk_Junkie Jul. 29 at 11:27 PM

$SXTP that’s a large stake. I’ll bite.

0 · Reply

BetsyBen Jul. 29 at 9:44 PM

$SXTP is getting attention off a fresh 13G filing. $DFNS pushed to $79 in after-hours. Fast move. Worth watching the next tape.

0 · Reply

stockobserver Jul. 29 at 9:41 PM

$SXTP No one cares

0 · Reply

60 Degrees Pharmaceuticals to sell shares and warrants in private placement

Jul 30, 2026, 2:23 PM EDT - 4 days ago

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

2026-07-29T21:15:29.000Z - 5 days ago

60 Degrees Pharma babesiosis interim readout planned by October 6

Jul 29, 2026, 4:03 PM EDT - 5 days ago

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

Jul 8, 2026, 8:01 AM EDT - 27 days ago

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

Jul 2, 2026, 8:00 AM EDT - 4 weeks ago

60 Degrees Pharmaceuticals Proxy statement: Proxy filing

2026-07-01T12:25:16.000Z - 4 weeks ago

60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study

Jul 1, 2026, 8:02 AM EDT - 4 weeks ago

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Jul 1, 2026, 8:00 AM EDT - 4 weeks ago

60 Degrees Pharmaceuticals Slides: Investor presentation

2026-06-11T13:01:09.000Z - 7 weeks ago

60 Degrees executes patent licensing agreement with Florida State

Jun 11, 2026, 8:03 AM EDT - 7 weeks ago

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Proxy statement: Proxy filing

2026-05-26T14:57:43.000Z - 2 months ago

60 Degrees announces early enrollment of first patient in trial of tafenoquine

May 26, 2026, 8:02 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

2026-05-20T16:00:11.000Z - 2 months ago

H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending

2026-05-20T15:55:36.000Z - 2 months ago

60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

May 15, 2026, 8:42 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

May 15, 2026, 7:00 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Earnings release: Q1 2026

Apr 16, 2026, 10:00 AM EDT - 3 months ago

60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

2026-04-15T12:37:07.000Z - 3 months ago

60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website

Mar 31, 2026, 7:01 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Announces 2025 Annual Results

Mar 30, 2026, 7:00 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Annual report: Q4 2025

2026-03-18T12:12:35.000Z - 4 months ago

60 Degrees submits NDIN to FDA for Australian Chestnut Extract

Mar 18, 2026, 8:01 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

2026-03-11T11:30:55.000Z - 5 months ago

60 Degrees reports all patients cured of babesiosis after tafenoquine treatment

Mar 11, 2026, 7:24 AM EDT - 5 months ago

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

2026-02-02T13:21:06.000Z - 6 months ago

60 Degrees expands access to Arakoda with GoodRx partnership

GDRX

Feb 2, 2026, 8:01 AM EST - 6 months ago

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

2026-01-27T16:30:17.000Z - 6 months ago

60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split

2026-01-22T14:15:44.000Z - 6 months ago

Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today

2026-01-22T13:27:13.000Z - 6 months ago

60 Degrees Pharmaceuticals announces partnership with Runway Health

2026-01-17T00:50:18.000Z - 7 months ago

60 Degrees Pharmaceuticals Inc trading halted, news pending

2026-01-15T13:21:52.000Z - 7 months ago

60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split

Jan 15, 2026, 8:01 AM EST - 7 months ago

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Dec 29, 2025, 8:01 AM EST - 7 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Dec 11, 2025, 8:01 AM EST - 8 months ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Nov 21, 2025, 8:01 AM EST - 9 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Nov 13, 2025, 4:00 PM EST - 9 months ago

60 Degrees Pharmaceuticals Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 9 months ago

60 Degrees Pharmaceuticals Quarterly report: Q3 2025

Nov 13, 2025, 1:51 PM EST - 9 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Oct 22, 2025, 4:15 PM EDT - 10 months ago

60 Degrees Pharmaceuticals Transcript: Investor Update

Oct 15, 2025, 7:14 AM EDT - 10 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Oct 9, 2025, 7:04 AM EDT - 10 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Sep 9, 2025, 3:30 PM EDT - 11 months ago

60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:02 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Aug 27, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Aug 21, 2025, 8:31 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:54 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 15, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Aug 13, 2025, 4:14 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Aug 13, 2025, 7:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Quarterly report: Q2 2025

Jul 16, 2025, 4:01 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 7:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 7, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Jun 4, 2025, 8:56 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 3, 2025, 8:49 AM EDT - 1 year ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

May 15, 2025, 4:31 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 12:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Quarterly report: Q1 2025

Apr 22, 2025, 8:44 AM EDT - 1 year ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 10, 2025, 8:31 AM EDT - 1 year ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 8, 2025, 8:31 AM EDT - 1 year ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Mar 27, 2025, 2:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Earnings release: Q4 2024

Mar 27, 2025, 2:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Annual report: Q4 2024

Mar 27, 2025, 2:30 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Slides: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Feb 21, 2025, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

Feb 20, 2025, 10:36 AM EST - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 14, 2025, 7:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Feb 11, 2025, 12:59 PM EST - 1 year ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 6, 2025, 2:07 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 1 year ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 28, 2025, 8:01 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 8, 2025, 8:02 AM EST - 1 year ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Dec 23, 2024, 8:57 AM EST - 1 year ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 11, 2024, 8:56 AM EST - 1 year ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 2, 2024, 4:05 PM EST - 1 year ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Nov 14, 2024, 2:31 PM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 13, 2024, 12:30 PM EST - 1 year ago

60 Degrees Pharmaceuticals Quarterly report: Q3 2024

Oct 15, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Oct 3, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 2, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Proxy statement: Proxy Filing

Sep 19, 2024, 8:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Registration statement: Registration Filing

Sep 4, 2024, 8:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Aug 28, 2024, 2:48 PM EDT - 2 years ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2024, 11:01 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 7:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

60 Degrees Pharmaceuticals Earnings release: Q2 2024

Aug 12, 2024, 9:12 AM EDT - 2 years ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 6, 2024, 9:26 AM EDT - 2 years ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

ChartChartist Jul. 30 at 7:42 PM

$SXTP nice offerings $PMAX bank central

0 · Reply

Hooparena Jul. 30 at 6:58 PM

0 · Reply

flychicken1991 Jul. 30 at 6:42 PM

0 · Reply

Hooparena Jul. 30 at 2:15 PM

0 · Reply

redog677 Jul. 29 at 11:48 PM

$SXTP they did leave a voicemail. It was about the shareholders meeting on Wednesday the 5th of Aug. I’ve never received a phone call like that. I thought it was interesting

0 · Reply

redog677 Jul. 29 at 11:45 PM

$SXTP I had a phone call from them today but wasn’t able to take the call.

0 · Reply

llchen1204 Jul. 29 at 11:45 PM

$SXTP tomorrow morning it will run as one of the top gainers

0 · Reply

Stonk_Junkie Jul. 29 at 11:27 PM

$SXTP that’s a large stake. I’ll bite.

0 · Reply

BetsyBen Jul. 29 at 9:44 PM

$SXTP is getting attention off a fresh 13G filing. $DFNS pushed to $79 in after-hours. Fast move. Worth watching the next tape.

0 · Reply

stockobserver Jul. 29 at 9:41 PM

$SXTP No one cares

0 · Reply

Candyman_Trader Jul. 29 at 9:33 PM

$SXTP on watch with fresh news

0 · Reply

StockTrader2727 Jul. 29 at 8:39 PM

$SXTP somebody knows something

0 · Reply

NoteToSelf5000 Jul. 29 at 8:18 PM

$SXTP Filing out 19% stake https://www.otcmarkets.com/filing/html?id=19643510&guid=moK-kp9g9uRBB3h

0 · Reply

focafoca99 Jul. 29 at 8:14 PM

$SXTP reached minimum enrollment for its severe babesiosis study, triggering an interim analysis by Oct 6.

0 · Reply

AlertsAndNews Jul. 27 at 7:58 PM

$SXTP patent headline into the close here.

0 · Reply

PatentGrants Jul. 27 at 7:56 PM

$SXTP 60 Degrees Pharmaceuticals will be issued US patent number 12,691,107 tomorrow titled "METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE". https://patentcenter.uspto.gov/applications/18300805/ifw/docs

0 · Reply

NolAsrtormZ Jul. 17 at 6:28 PM

$SXTP earnings Aug 17 estimated- curious on cash n whos paying 4 continuous drug yrial

0 · Reply

NolAsrtormZ Jul. 17 at 6:26 PM

$SXTP Wait 4 more share offerings- data a ways out- good lord CEos need to eat great

0 · Reply

NolAsrtormZ Jul. 17 at 6:25 PM

$SXTP niche market- cool- i hate ticks

0 · Reply

MASVRE Jul. 15 at 4:19 PM

$SXTP Their Malaria medicine will be used as a supplement to help this current Outbreak!

0 · Reply

prismmarketview Jul. 9 at 1:04 PM

$SXTP adds more pipeline optionality. New exclusive option with Florida State University Research Foundation gives them first crack at castanospermine for Powassan, TBE, alpha-gal and post-treatment Lyme. Nice fit with their vector-borne niche. #SXTP #Biotech #SmallCaps #TickBorneDisease https://prismmarketview.com/60-degrees-pharmaceuticals-secures-new-castanospermine-opportunity-in-tick-borne-disease/

0 · Reply

BULLETSTOCK Jul. 8 at 12:43 PM

$IOTR or $SXTP You Choose 🚀 $SXTP 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

1 · Reply

Market Cap	3.11M
Revenue (ttm)	1.41M
Net Income (ttm)	-7.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-522.70%
Debt to Equity Ratio	0.00

Volume	81,200
Avg Vol	118,616
Day's Range	N/A - N/A
Shares Out	2.66M
Stochastic %K	17%
Beta	2.47
Analysts	Sell
Price Target	$3.70